Berlin - Delayed Quote EUR

UroGen Pharma Ltd. R (UR8.BE)

10.20

0.00

(0.00%)

At close: May 2 at 9:40:04 PM GMT+2

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

PRINCETON, N.J., May 01, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2025 financial results on Monday, May 12, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

Business Wire 3 days ago

URGN
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?

Urogen Pharma (URGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 5 days ago

URGN

LQDA
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

PRINCETON, N.J., April 27, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients.

Business Wire 7 days ago

URGN
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

PRINCETON, N.J., April 27, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without nega

Business Wire 7 days ago

URGN
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

PRINCETON, N.J., April 27, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treat

Business Wire 7 days ago

URGN
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

PRINCETON, N.J., April 26, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced an updated 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. These data were featured today in an Oral Presentation Session (Abstr

Business Wire 8 days ago

URGN
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., April 26, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC).

Business Wire 8 days ago

URGN
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

PRINCETON, N.J., April 14, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that data on investigational drug UGN-102 (mitomycin) for intravesical solution, JELMYTO (mitomycin) for pyelocalyceal solution and UGN-301 (zalifrelimab) will be presented at the American Urological Association (AUA) 2025 Annual Meeting being held in Las Vegas, Nevada from April 26-29.

Business Wire 20 days ago

URGN
High Growth Tech Stocks In The US To Watch April 2025

Over the last 7 days, the United States market has experienced a 10% decline, contributing to an overall drop of 3.8% over the past year, although earnings are anticipated to grow by 14% annually in the coming years. In such a fluctuating environment, identifying high growth tech stocks involves looking for companies with strong fundamentals and innovative potential that can thrive despite short-term market volatility.

Simply Wall St. 26 days ago

ORGO

URGN

OB
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...

UroGen Pharma Ltd (URGN) showcases promising drug developments and market expansion plans amidst rising expenses and net losses.

GuruFocus.com last month

URGN
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.11% and 6.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

URGN
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

PRINCETON, N.J., March 10, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent developments.

Business Wire last month

URGN
Exploring High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet in the longer term, it has risen by 11% over the past year with earnings forecasted to grow by 14% annually. In this context of fluctuating short-term performance and promising long-term growth prospects, identifying high growth tech stocks involves evaluating companies that demonstrate strong innovation potential and resilience in adapting to changing market conditions.

Simply Wall St. last month

SPRY

URGN

PEGA
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., March 07, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 7 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the cont

Business Wire last month

URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

PRINCETON, N.J., February 27, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2024 financial results on Monday, March 10, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

Business Wire 2 months ago

URGN
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where UroGen Pharma Ltd. (NASDAQ:URGN) stands against other best small-cap growth stocks to buy now. Are Small-Cap Stocks Poised for Growth? On November 4, 2024, Nick Sheridan, Portfolio Manager at […]

Insider Monkey 2 months ago

URGN
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

PRINCETON, N.J., February 24, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference to take place on March 3-5, 2025.

Business Wire 2 months ago

URGN
UroGen acquires IconOVir’s oncolytic virus assets

UroGen has initiated several research partnerships to investigate its RTGel technology.

Pharmaceutical Technology 2 months ago

URGN
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

PRINCETON, N.J., February 20, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. (IconOVir). In addition, UroGen also announced that it has entered into multiple strategic research collaborations to explore

Business Wire 2 months ago

URGN
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

PRINCETON, N.J., February 14, 2025--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality on the response to UGN-102, an investigational drug in development for treatment of LG-IR-NMIBC. Analyses of pre-specified subgroups showed comparable CR rates and DOR p

Business Wire 2 months ago

URGN

Performance Overview

Return	UR8.BE	S&P 500 (^GSPC)
YTD	--	-3.31%
1-Year	-23.31%	+12.29%
3-Year	-43.02%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

UroGen Pharma Ltd. R (UR8.BE)

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

High Growth Tech Stocks In The US To Watch April 2025

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

Exploring High Growth Tech Stocks in the US Market

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen acquires IconOVir’s oncolytic virus assets

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

Performance Overview